Penumbra Inc PEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024
-
Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash™ 2.0 and Lightning Bolt™ 7 - in Europe
-
Penumbra, Inc. to Present at the Baird Global Healthcare Conference
-
Penumbra, Inc. to Present at the Wells Fargo Healthcare Conference
-
Penumbra, Inc. Announces $200 Million Share Repurchase Authorization
-
Penumbra, Inc. to Present at the Canaccord Genuity Growth Conference
-
Penumbra, Inc. Reports Second Quarter 2024 Financial Results
Trading Information
- Previous Close Price
- $194.99
- Day Range
- $192.26–198.89
- 52-Week Range
- $148.00–277.34
- Bid/Ask
- $188.26 / $200.98
- Market Cap
- $7.56 Bil
- Volume/Avg
- 243,639 / 460,232
Key Statistics
- Price/Earnings (Normalized)
- 78.52
- Price/Sales
- 6.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 4,200
- Website
- https://www.penumbrainc.com
Comparables
Valuation
|
Metric
|
PEN
|
688016
|
ZIMV
|
|---|---|---|---|
Price/Earnings (Normalized) | 78.52 | 22.39 | 45.82 |
Price/Book Value | 6.51 | 3.46 | 1.12 |
Price/Sales | 6.70 | 9.68 | 0.98 |
Price/Cash Flow | 40.70 | 19.38 | 49.02 |
Price/Earnings
PEN
688016
ZIMV
Financial Strength
|
Metric
|
PEN
|
688016
|
ZIMV
|
|---|---|---|---|
Quick Ratio | 3.58 | 8.91 | 1.06 |
Current Ratio | 6.25 | 9.53 | 1.94 |
Interest Coverage | — | 413.50 | 0.07 |
Quick Ratio
PEN
688016
ZIMV
Profitability
|
Metric
|
PEN
|
688016
|
ZIMV
|
|---|---|---|---|
Return on Assets (Normalized) | 6.44% | 16.12% | 0.60% |
Return on Equity (Normalized) | 8.53% | 18.19% | 1.42% |
Return on Invested Capital (Normalized) | 6.53% | 17.54% | 1.51% |
Return on Assets
PEN
688016
ZIMV
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Wwlmnyfbj | Fgvxjps | $196.0 Bil | |||
| Stryker Corp
SYK
| Wrjtqwbs | Zkql | $133.8 Bil | |||
| Boston Scientific Corp
BSX
| Sfcrzmmn | Jgkwsd | $124.5 Bil | |||
| Medtronic PLC
MDT
| Vmyknwhg | Pzzwz | $113.2 Bil | |||
| Edwards Lifesciences Corp
EW
| Gkqjnmsslp | Mjgbdp | $39.5 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Bvf | Ddbml | $30.2 Bil | |||
| DexCom Inc
DXCM
| Fzzzzqrlm | Jzqrz | $27.3 Bil | |||
| Steris PLC
STE
| Fklpbjh | Snkdvr | $22.8 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Kgkbykcd | Wtpt | $21.3 Bil | |||
| Insulet Corp
PODD
| Tpjmykrspv | Bzgzt | $16.1 Bil |
United States